Anavex Life Sciences Corp (AVXL)

[makemydaze]

A few questions regarding the June Presentation

http://www.anavex.com/wp-content/uploads/2020/06/Anavex-Presentation-June-2020.pdf

On page 24 - Regarding PDD: Why did Anavex choose to use the same primary endpoint as did Eli Lilly? (just so we can compare outcome efficacy?)

"Primary Outcome Measures :

Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention [ Time Frame: 14 weeks ]

Change from Baseline to End of Treatment in Continuity of Attention as measured by Cognitive Drug Research (CDR) Computerized Assessment System Continuity of Attention test

Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 14 weeks ]
Assess the safety and tolerability of ANAVEX2-73 compared to placebo"

https://clinicaltrials.gov/ct2/show/NCT03774459

How much of a response to the Continuity of Attention would have to be achieved for Missling to consider going for PA?

From page 24 of the June presentation - why do they try to correlate the Continuity of Attention response(in PDD) to the Cogstate IDN response in AD? Is that just to cross reference results?

"Identification (IDN) task – a choice reaction time paradigm that measures visual attention. Reaction time was the primary outcome measure."

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4273919/